<DOC>
	<DOCNO>NCT02154867</DOCNO>
	<brief_summary>Fecal Microbial Transplantation Treatment Irritable Bowel Syndrome ; Double Blinded Placebo Controlled Trial - REFIT project Irritable bowel syndrome ( IBS ) condition characterize variable complaint like diarrhoea , bloat abdominal pain , may result considerably reduce quality life increase sickness absence . The prevalence IBS general population may high 15 per cent depend diagnostic criterion use . The pathophysiology IBS poorly understood theory visceral hypersensitivity , micro-inflammation le well founded theory state . So far , measurement test affirm diagnosis , exclusion organic disease combination typical symptom pattern accord Rome classification set diagnosis . Earlier non-controlled case report show convincing effect fecal microbial transplantation ( FMT ) IBS patient . However , placebo control trial perform condition . Changes gut microbiome may important factor IBS pathogenesis . Microbiome analysis reveal change microbiome composition may trigger change visceral sensibility pain perception . The fecal microbial transplantation ( FMT ) procedure use primarily treat clostridium difficile infection . Few minor side effect report . Hypothesis : IBS cause imbalance gut microbiome may reset transplant microbiome sample healthy donor . Aim study : - To test clinical effect FMT patient IBS - To describe fecal microbiome IBS patient - To describe change fecal microbiome IBS patient follow FMT The REFIT study perform randomize placebo-controlled double blind trial FMT IBS accord Rome 3 criterion . A study group 60 IBS ( diarrhoea variant ) patient recruit general practice allocate active ( 30 ) placebo ( 30 ) block randomization . Donors 15 healthy volunteer risk behaviour pre-screening communicable disease perform . Outcome measure clinical assessment IBS-severity scoring system ( IBS-SSS ) 0 , 1 , 3 , 6 , 12 month . Microbiome analysis perform metagenomic sequencing ( University Troms√∏ ) 0 , 3 , 12 month patient , inclusion donor .</brief_summary>
	<brief_title>Fecal Microbial Transplantation Treatment Irritable Bowel Syndrome ; Double Blinded Placebo Controlled Trial .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Inclusion Criteria patient : Patients IBSD accord Roma 3 criterion Exclusion Criteria patient : Immunomodulating medication Nocturnal abdominal pain Constant abdominal pain Alarm symptom like rectal bleeding , weight loss , nightsweats Symptomatic heart/vascular/lung disease Renal failure Known food allergy Microscopic/collagenous colitis noncompliant BMI &lt; 18 Inclusion criterion donor : healthy volunteer Exclusion criterion donor Tattoos , imprison pierce last 3 month Any history chronic diarrhoea , constipation , inflammatory bowel disease , irritable bowel disease , colorectal polyp cancer , immunosuppression , morbid obesity , metabolic syndrome , atopica , fatigue positive test hepatitis B , C , HIV , treponema pallidum sexual high risk habit antibiotic treatment past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>IBS-D</keyword>
	<keyword>FMT</keyword>
	<keyword>metagenomics</keyword>
	<keyword>gut microbiome</keyword>
</DOC>